Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study.
Staab D, Pariser D, Gottlieb AB, Kaufmann R, Eichenfield LF, Langley RG, Scott G, Ebelin ME, Barilla D, Schmidli H, Burtin P. Staab D, et al. Among authors: ebelin me. Pediatr Dermatol. 2005 Sep-Oct;22(5):465-71. doi: 10.1111/j.1525-1470.2005.00128.x. Pediatr Dermatol. 2005. PMID: 16191004 Clinical Trial.
Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated.
Rappersberger K, Komar M, Ebelin ME, Scott G, Burtin P, Greig G, Kehren J, Chibout SD, Cordier A, Holter W, Richter L, Oberbauer R, Stuetz A, Wolff K. Rappersberger K, et al. Among authors: ebelin me. J Invest Dermatol. 2002 Oct;119(4):876-87. doi: 10.1046/j.1523-1747.2002.00694.x. J Invest Dermatol. 2002. PMID: 12406334 Free article. Clinical Trial.
Predictivity of an in vitro model for acute and chronic skin irritation (SkinEthic) applied to the testing of topical vehicles.
de Brugerolle de Fraissinette, Picarles V, Chibout S, Kolopp M, Medina J, Burtin P, Ebelin ME, Osborne S, Mayer FK, Spake A, Rosdy M, De Wever B, Ettlin RA, Cordier A. de Brugerolle de Fraissinette, et al. Among authors: ebelin me. Cell Biol Toxicol. 1999 Apr;15(2):121-35. doi: 10.1023/a:1007577515215. Cell Biol Toxicol. 1999. PMID: 10408359